Results 161 to 170 of about 960,807 (326)

5‐Methylcytosine Analysis of miRNAs in Minimal Change Disease

open access: yesBiotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Minimal change disease (MCD) is a glomerular disorder, which is the most common cause of nephrotic syndrome in children. Additionally, the prevalence of MCD in adults has been increasing in recent years. During protein synthesis, noncoding RNAs can be regulated through a variety of modifications, which helps preserve biological diversity and ...
Huiyi Zeng   +14 more
wiley   +1 more source

Blood cholesterol levels of hypercholesterolemic rat (Rattus norvegicus) after VCO treatment [PDF]

open access: yes, 2009
Abstrak. Harini M, Astirin OP. 2009. Kadar kolesterol darah tikus putih (Rattus norvegicus) hiperkolesterolemik setelah perlakuan VCO. Nusantara Bioscience 1: 53-58.
ASTIRIN, OKID PARAMA, HARINI, MARTI
core   +2 more sources

Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease.

open access: yesJournal of the American College of Cardiology, 2020
O. Castañer   +22 more
semanticscholar   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

Direct measurement of LDL cholesterol [PDF]

open access: yesClinical Chemistry, 1996
S S, Levinson, J J, Maciejko
openaire   +2 more sources

Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses.
Sooyoun Lee   +5 more
wiley   +1 more source

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism

open access: yesHepatology, EarlyView., 2022
Hepatic APOF transcript levels correlate inversely with plasma TG and hepatic steatosis in humans. ApoF expression in mice promotes VLDL‐TG production and lipoprotein remnant clearance in mice. Abstract Background NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD,
Audrey Deprince   +30 more
wiley   +1 more source

Statins for primary and secondary prevention in the oldest old : an overview of the existing evidence [PDF]

open access: yes, 2012
Hypercholesterolemia, although a modifiable risk factor for cardiovascular disease, is still one of the leading causes of death among older people in western countries.
Petrovic, Mirko   +2 more
core   +1 more source

Serum cholesterol LDL and 90-day mortality in patients with intracerebral hemorrhage.

open access: yesStroke, 2009
J. Ramírez-Moreno   +6 more
semanticscholar   +1 more source

Long‐term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real‐world cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Elexacaftor/tezacaftor/ivacaftor (ETI) has markedly improved cystic fibrosis (CF) outcomes. However, its long‐term impact on nutrition, metabolism and liver health remains underexplored. We assessed 30‐month changes in pulmonary, nutritional, metabolic and inflammatory markers in people with CF (PwCF) homozygous for F508del.
Nicola Perrotta   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy